Introduction

This chapter explores the upcoming announcement by the Biden administration regarding drug price negotiations in Medicare. It discusses the incentives involved for Medicare and pharmaceutical companies, the state of negotiations in Congress, and the new powers granted to Medicare for reducing drug company subsidies.